Using stem cells from umbilical cords to treat severe liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and effectiveness of mesenchymal stem cells (MSCs) derived from umbilical cords in treating patients with decompensated cirrhosis. The study aims to provide an alternative to liver transplantation, which is limited by donor availability and complications. Participants will receive either the MSC treatment or a placebo, and their liver function will be monitored throughout the trial. The research builds on previous findings that suggest MSC therapy can improve liver function and patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Willing to provide written informed consent;
2. Aged 18 to 75 years (including 18 and 75 years), male or female;
3. Patients diagnosed with decompensated liver cirrhosis based on clinical findings, laboratory tests, imaging findings and/or representative pathological findings (decompensated liver cirrhosis is defined as the occurrence of at least one serious complication, including esophageal and gastric varices bleeding, hepatic encephalopathy, ascites, spontaneous bacterial peritonitis and other serious complications);
4. The Model for End-stage Liver Disease (MELD) score 15 to 30 points.

Exclusion Criteria:

1. Appearance of active variceal bleeding, overt hepatic encephalopathy (HE), refractory ascites or hepatorenal syndrome within 1 month prior to screening visit.
2. Uncontrolled severe infection within 2 weeks of screening.
3. Patients with hepatitis B virus-related decompensated liver cirrhosis may discontinue antiviral therapy during the study, or those who with antiviral therapy for HBV for less than 12 months, or hepatitis B virus (HBV) DNA ≥ detection limit at the time of screening.
4. Patients with hepatitis C virus-related decompensated liver cirrhosis may discontinue antiviral therapy during the study, or those who with antiviral therapy for HCV for less than 12 months, or hepatitis C virus (HCV) RNA ≥ detection limit at the time of screening (except HCV RNA\< detection limit without any antiviral treatment).
5. Patients under treatment with corticosteroids for autoimmune hepatitis for less than 6 months.
6. Trans-jugular intrahepatic portosystemic shunts (TIPS) insertion within 6 months prior to study inclusion.
7. Active drinkers with alcohol-related decompensated cirrhosis are unwilling to stop alcohol abuse after inclusion.
8. Significant renal insufficiency (serum creatinine ≥ 1.2 times upper normal limit); Severe electrolyte abnormality (serum sodium level \< 125 mmol/L); Severe leukopenia (white blood cell count \< 1 × 10E9/L).
9. Patients with biliary obstruction, or portal vein spongiosis.
10. Patients with surgical history such as splenic cut-off flow.
11. Patients with malignant tumors within 5 years, except those with basal cell carcinoma, squamous cell carcinoma and/or carcinoma in situ who had received curative treatment and curative resection.
12. Patients with a prior history of major organ transplantation or complicated with significant disease of heart, lung, kidney, blood, endocrine and other systems.
13. Drug abuse, drug dependence and patients who receive methadone treatment or with psychosis.
14. Against the human immunodeficiency virus antibody (Anti - HIV) or syphilis antibody test results were positive.
15. Pregnancy, lactation or with recent fertility plan during the test and 6 months after the test.
16. Highly allergic, or have a history of severe allergies, known severe allergies to the investigational drug or any of the excipients.
17. History of pulmonary embolism.
18. Patients who had previously received stem cell therapy or were intolerant to cell therapy.
19. The proposed line of liver transplants within three months.
20. Participants in other clinical trials within the last 3 months.
21. Any other clinical condition which the investigator considers would make the patient unsuitable for the trial.

Where it's running

• Hainan hospital of Chinese PLA General Hospital
  Sanya, Hainan, China Recruiting
• Shanghai Changzheng Hospital
  Shanghai, Shanghai Municipality, China Recruiting
• Beijing 302 Hospital
  Beijing, China Recruiting
• The First Hospital of Lanzhou University
  Lanzhou, Gansu, China Not yet recruiting
• Third Affiliated Hospital, Sun Yat-Sen University
  Guangzhou, Guangdong, China Not yet recruiting
• Jin Yin-tan Hospital
  Wuhan, Hubei, China Not yet recruiting

Study contacts

• Study coordinator: Lei Shi, MD,PhD
• Email: shilei302@126.com
• Phone: 86-10-66949623

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Developing and validating a formula to detect major kidney events in people with decompensated cirrhosis and ascites

  This observational study aims to test a new equation that helps identify major adverse kidney events in adults with decompensated cirrhosis and ascites who have stable kidney function.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT07794787

• Comparing BCAA and Rifaximin for Preventing Hepatic Encephalopathy Recurrence

  This study is testing whether taking branched-chain amino acids or rifaximin can help people who have recently recovered from liver-related brain issues avoid having those problems come back.

  Recruiting Phase 4 Post Graduate Institute of Medical Education and Research, Chandigarh · Chandigarh · NCT06538077

• FMT for decompensated cirrhosis: a multicenter phase 3 test

  This phase 3 trial tests whether fecal microbiota transplantation from healthy donors can help people with decompensated cirrhosis.

  Recruiting at 8 sites Phase 3 Consorcio Centro de Investigación Biomédica en Red (CIBER) · Barcelona and 7 other locations · NCT06533852

• Carvedilol plus simvastatin versus carvedilol alone for cirrhosis-related heart dysfunction

  This trial will test whether adding simvastatin to carvedilol helps adults with cirrhosis and cirrhotic cardiomyopathy reduce liver decompensation and improve survival.

  Recruiting Post Graduate Institute of Medical Education and Research, Chandigarh · Chandigarh · NCT06431919

• Home-based care model for patients with cirrhosis

  This study is testing a home care program for people with serious liver disease to see if it helps them feel better and be more satisfied with their care.

  Recruiting Indiana University · Indianapolis, Indiana · NCT06396897

• Using smartphone technology to improve care for patients with cirrhosis

  This study is testing whether a new smartphone monitoring system can help people with advanced liver disease manage their condition better and avoid hospital visits compared to regular care.

  Recruiting at 14 sites University College, London · Birmingham and 14 other locations · NCT06223893

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.